Zymeworks is a clinical-stage biopharmaceutical company that develops and commercializes biotherapeutics for cancer treatment. Its lead product candidates include Zanidatamab and zanidatamab zovodotin, both in clinical trials for the treatment of various cancers. The company also develops preclinical product candidates and discovery-stage programs in oncology and has partnerships with several pharmaceutical companies. Zymeworks was founded in 2003 and is based in Vancouver, Canada.